<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30243965</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-6351</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>121</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
          <ISOAbbreviation>Food Chem Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Apoptotic cell death induced by Z-Ligustilidein human ovarian cancer cells and role of NRF2.</ArticleTitle>
        <Pagination>
          <StartPage>631</StartPage>
          <EndPage>638</EndPage>
          <MedlinePgn>631-638</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fct.2018.09.041</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0278-6915(18)30684-7</ELocationID>
        <Abstract>
          <AbstractText>Z-Ligustilide is the most potent bioactive component of Angelica sinensis, which is widely used in Chinese traditional medicine. Z-Ligustilide selectively affected ovarian cancer cell survival in a dose dependent manner. Z-Ligustilide induced apoptotic cell death was determined by flow cytometry. We also demonstrated that apoptotic cell death was triggered by Z-Ligustilideinduced oxidative stress and mitochondria played an active role. Mitochondrial polarization was reduced by Z-Ligustilidewhereas mitochondrial superoxide formation was increased. NRF2 was induced by Z-Ligustilide in OVCAR-3 cells at epigenetic level and its downstream antioxidant defense genesHeme oxygenase-1,NAD(P)H Quinone Dehydrogenase 1, UDP Glucuronosyltransferase Family 1 Member A1and Glutamate-Cysteine Ligase. NRF2 knockdown by siRNA resulted increased cell death by Z-Ligustilide in ovarian cancer cells. Our result demonstrated the pro-survival role of NRF2 in Z-Ligustilide induced ovarian cancer cell death.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lang</LastName>
            <ForeName>Fangfang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: langff77@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qu</LastName>
            <ForeName>Jinfeng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: ququ1258@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Haiqin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: 1018512938@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lanyu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: ljjandlly@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhi</LastName>
            <ForeName>Yuanyuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: zhiyuanyuan163@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yanping</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: 841869042@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Zhenghui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: fzh2k@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Enkui</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Qianfoshan Hospital, Affiliated with Shandong University, Jinan, China. Electronic address: haoenkui@sdu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>09</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Food Chem Toxicol</MedlineTA>
        <NlmUniqueID>8207483</NlmUniqueID>
        <ISSNLinking>0278-6915</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4431-01-0</RegistryNumber>
          <NameOfSubstance UI="C027820">ligustilide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL659KIY4X</RegistryNumber>
          <NameOfSubstance UI="D015107">4-Butyrolactone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015107" MajorTopicYN="N">4-Butyrolactone</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Ligustilide</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30243965</ArticleId>
        <ArticleId IdType="doi">10.1016/j.fct.2018.09.041</ArticleId>
        <ArticleId IdType="pii">S0278-6915(18)30684-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27638861</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>06</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-8514</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer therapeutics</Title>
          <ISOAbbreviation>Mol Cancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis.</ArticleTitle>
        <Pagination>
          <StartPage>3000</StartPage>
          <EndPage>3014</EndPage>
          <MedlinePgn>3000-3014</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Alkylating agents are a commonly used cytotoxic class of anticancer drugs. Understanding the mechanisms whereby cells respond to these drugs is key to identify means to improve therapy while reducing toxicity. By integrating genome-wide gene expression profiling, protein analysis, and functional cell validation, we herein demonstrated a direct relationship between NRF2 and Endoplasmic Reticulum (ER) stress pathways in response to alkylating agents, which is coordinated by the availability of glutathione (GSH) pools. GSH is essential for both drug detoxification and protein thiol homeostasis within the ER, thus inhibiting ER stress induction and promoting survival, an effect independent of its antioxidant role. NRF2 accumulation induced by alkylating agents resulted in increased GSH synthesis via GCLC/GCLM enzyme, and interfering with this NRF2 response by either NRF2 knockdown or GCLC/GCLM inhibition with buthionine sulfoximine caused accumulation of damaged proteins within the ER, leading to PERK-dependent apoptosis. Conversely, upregulation of NRF2, through KEAP1 depletion or NRF2-myc overexpression, or increasing GSH levels with N-acetylcysteine or glutathione-ethyl-ester, decreased ER stress and abrogated alkylating agents-induced cell death. Based on these results, we identified a subset of lung and head-and-neck carcinomas with mutations in either KEAP1 or NRF2/NFE2L2 genes that correlate with NRF2 target overexpression and poor survival. In KEAP1-mutant cancer cells, NRF2 knockdown and GSH depletion increased cell sensitivity via ER stress induction in a mechanism specific to alkylating drugs. Overall, we show that the NRF2-GSH influence on ER homeostasis implicates defects in NRF2-GSH or ER stress machineries as affecting alkylating therapy toxicity. Mol Cancer Ther; 15(12); 3000-14. ©2016 AACR.</AbstractText>
          <CopyrightInformation>&#xa9;2016 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zanotto-Filho</LastName>
            <ForeName>Alfeu</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masamsetti</LastName>
            <ForeName>V Pragathi</ForeName>
            <Initials>VP</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Children's Medical Research Institute, Westmead, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loranc</LastName>
            <ForeName>Eva</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tonapi</LastName>
            <ForeName>Sonal S</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorthi</LastName>
            <ForeName>Aparna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bernard</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonçalves</LastName>
            <ForeName>Rosângela Mayer</ForeName>
            <Initials>RM</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moreira</LastName>
            <ForeName>José C F</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yidong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bishop</LastName>
            <ForeName>Alexander J R</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas. bishopa@uthscsa.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R15 ES019128</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA148724</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA054174</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K22 ES012264</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA152063</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>09</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Cancer Ther</MedlineTA>
        <NlmUniqueID>101132535</NlmUniqueID>
        <ISSNLinking>1535-7163</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013438">Sulfhydryl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018906" MajorTopicYN="N">Antineoplastic Agents, Alkylating</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059865" MajorTopicYN="N">Endoplasmic Reticulum Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013438" MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019892" MajorTopicYN="N">eIF-2 Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that no conflict of interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27638861</ArticleId>
        <ArticleId IdType="mid">NIHMS816926</ArticleId>
        <ArticleId IdType="pmc">PMC5136348</ArticleId>
        <ArticleId IdType="doi">10.1158/1535-7163.MCT-16-0271</ArticleId>
        <ArticleId IdType="pii">1535-7163.MCT-16-0271</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hernandez-Aya LF, Gonzalez-Angulo AM. Adjuvant systemic therapies in breast cancer. Surg Clin North Am. 2013;93:473&#x2013;491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23464697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones RB, Matthes S, Dufton C, Bearman SI, Stemmer SM, Meyers S, et al. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast Cancer Res Treat. 1993;26(Suppl):S11&#x2013;S17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8400329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842&#x2013;1850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24193082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585&#x2013;2597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10914698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013;5:S565&#x2013;S578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3804877</ArticleId>
            <ArticleId IdType="pubmed">24163749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52:377&#x2013;391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22094224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, Bratlie MS, et al. Alkylation damage in DNA and RNA--repair mechanisms and medical significance. DNA Repair (Amst) 2004;3:1389&#x2013;1407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15380096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malet-Martino M, Gilard V, Martino R. The analysis of cyclophosphamide and its metabolites. Curr Pharm Des. 1999;5:561&#x2013;586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10469892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altieri F, Grillo C, Maceroni M, Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10:891&#x2013;937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18205545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Workman CT, Mak HC, McCuine S, Tagne JB, Agarwal M, Ozier O, et al. A systems approach to mapping DNA damage response pathways. Science. 2006;312:1054&#x2013;1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2811083</ArticleId>
            <ArticleId IdType="pubmed">16709784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179&#x2013;2191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3814639</ArticleId>
            <ArticleId IdType="pubmed">24142871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Paonessa JD, Zhang Y. Mechanism of chemical activation of Nrf2. PLoS One. 2012;7:e35122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338841</ArticleId>
            <ArticleId IdType="pubmed">22558124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1991;20:194&#x2013;208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2025981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin JH, Li H, Zhang Y, Ron D, Walter P. Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One. 2009;4:e4170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2614882</ArticleId>
            <ArticleId IdType="pubmed">19137072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900&#x2013;917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2887297</ArticleId>
            <ArticleId IdType="pubmed">20303879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001;153:1011&#x2013;1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2174339</ArticleId>
            <ArticleId IdType="pubmed">11381086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, et al. IRE1 signaling affects cell fate during the unfolded protein response. Science. 2007;318:944&#x2013;949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3670588</ArticleId>
            <ArticleId IdType="pubmed">17991856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Hendershot LM. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem. 2003;278:34864&#x2013;34873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12840028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birk J, Meyer M, Aller I, Hansen HG, Odermatt A, Dick TP, et al. Endoplasmic reticulum: reduced and oxidized glutathione revisited. J Cell Sci. 2013;126:1604&#x2013;1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23424194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raturi A, Mutus B. Characterization of redox state and reductase activity of protein disulfide isomerase under different redox environments using a sensitive fluorescent assay. Free Radic Biol Med. 2007;43:62&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17561094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarthi S, Jessop CE, Bulleid NJ. The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep. 2006;7:271&#x2013;275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1456887</ArticleId>
            <ArticleId IdType="pubmed">16607396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanotto-Filho A, Dashnamoorthy R, Loranc E, de Souza LH, Moreira JC, Suresh U, et al. Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One. 2016;11:e0153970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4839732</ArticleId>
            <ArticleId IdType="pubmed">27100653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolova T, Ensminger M, Lobrich M, Kaina B. Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate. DNA Repair (Amst) 2010;9:1050&#x2013;1063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20708982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanotto-Filho A, Delgado-Canedo A, Schroder R, Becker M, Klamt F, Moreira JC. The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett. 2010;288:192&#x2013;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19646807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox DP, Cardozo-Pelaez F. High Throughput Method for Assessment of Cellular Reduced Glutathione in Mammalian Cells. J Environ Prot Sci. 2007;1:23&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2867479</ArticleId>
            <ArticleId IdType="pubmed">20463849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JS, Raines RT. Dibromobimane as a fluorescent crosslinking reagent. Anal Biochem. 1995;225:174&#x2013;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7778775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol. 2005;25:162&#x2013;171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC538799</ArticleId>
            <ArticleId IdType="pubmed">15601839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013;8:e74250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3774754</ArticleId>
            <ArticleId IdType="pubmed">24066126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160307</ArticleId>
            <ArticleId IdType="pubmed">23550210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401&#x2013;404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3956037</ArticleId>
            <ArticleId IdType="pubmed">22588877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komiya S, Gebhardt MC, Mangham DC, Inoue A. Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J Orthop Res. 1998;16:15&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9565068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koharyova M, Kollarova M. Thioredoxin system - a novel therapeutic target. Gen Physiol Biophys. 2015;34:221&#x2013;233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25926547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol. 2003;23:7198&#x2013;7209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC230321</ArticleId>
            <ArticleId IdType="pubmed">14517290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Ni M, Lee B, Barron E, Hinton DR, Lee AS. The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. Cell Death Differ. 2008;15:1460&#x2013;1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758056</ArticleId>
            <ArticleId IdType="pubmed">18551133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008;68:1303&#x2013;1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18316592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3:e420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1584412</ArticleId>
            <ArticleId IdType="pubmed">17020408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canning P, Sorrell FJ, Bullock AN. Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med. 2015;88:101&#x2013;107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4668279</ArticleId>
            <ArticleId IdType="pubmed">26057936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73:6289&#x2013;6298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3856255</ArticleId>
            <ArticleId IdType="pubmed">23980093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharp SY, Smith V, Hobbs S, Kelland LR. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer. 1998;78:175&#x2013;180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2062892</ArticleId>
            <ArticleId IdType="pubmed">9683290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64:706&#x2013;721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3400836</ArticleId>
            <ArticleId IdType="pubmed">22659329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen X, Buckley B, McCandlish E, Goedken MJ, Syed S, Pelis R, et al. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol. 2014;184:1299&#x2013;1308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4005989</ArticleId>
            <ArticleId IdType="pubmed">24641901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syu JP, Chi JT, Kung HN. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4924742</ArticleId>
            <ArticleId IdType="pubmed">26894974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci. 2007;98:216&#x2013;230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17434952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurgen SG, Erdogan D, Elmas C, Kaplanoglu GT, Ozer C. Chemoprotective effect of ascorbic acid, alpha-tocopherol, and selenium on cyclophosphamide-induced toxicity in the rat ovarium. Nutrition. 2013;29:777&#x2013;784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23422538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuce G, Cetinkaya S, Koc T, Esen HH, Limandal C, Balci T, et al. Chemoprotective effect of vitamin E in cyclophosphamide-induced hepatotoxicity in rats. Chem Biol Interact. 2015;232:7&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25779342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross E, Kastner DB, Kaiser CA, Fass D. Structure of Ero1p, source of disulfide bonds for oxidative protein folding in the cell. Cell. 2004;117:601&#x2013;610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15163408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Bartels MJ, Pottenger LH, Gollapudi BB. Differential adduction of proteins vs. deoxynucleosides by methyl methanesulfonate and 1-methyl-1-nitrosourea in vitro. Rapid Commun Mass Spectrom. 2005;19:438&#x2013;448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15655799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paik WK, DiMaria P, Kim S, Magee PN, Lotlikar PD. Alkylation of protein by methyl methanesulfonate and 1-methyl-1-nitrosourea in vitro. Cancer Lett. 1984;23:9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6331636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trezl L, Park KS, Kim S, Paik WK. Studies on in vitro S-methylation of naturally occurring thiol compounds with N-methyl-N-nitrosourea and methyl methanesulfonate. Environ Res. 1987;43:417&#x2013;426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3608940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karasawa T, Sibrian-Vazquez M, Strongin RM, Steyger PS. Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds. PLoS One. 2013;8:e66220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3670892</ArticleId>
            <ArticleId IdType="pubmed">23755301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi S, Tan P, Yan B, Gao R, Zhao J, Wang J, et al. ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells. Oncol Rep. 2016;35:2606&#x2013;2614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4811398</ArticleId>
            <ArticleId IdType="pubmed">26985651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Wang C, Su J, Xie Q, Ma L, Zeng L, et al. Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis. Oncol Rep. 2015;34:3051&#x2013;3060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26398138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabik CA, Fishel ML, Holleran JL, Kasza K, Kelley MR, Egorin MJ, et al. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther. 2008;327:442&#x2013;452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3785988</ArticleId>
            <ArticleId IdType="pubmed">18664592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, Zhang XD. Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis. 2009;30:197&#x2013;204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18842681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Wang W, Dong H, Li Y, Li L, Han L, et al. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78. Oncol Rep. 2014;31:2525&#x2013;2534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24756776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocha CR, Garcia CC, Vieira DB, Quinet A, de Andrade-Lima LC, Munford V, et al. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis. 2014;5:e1505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4649538</ArticleId>
            <ArticleId IdType="pubmed">25356874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol. 2015;32:69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25691294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanotto-Filho A, Braganhol E, Klafke K, Figueiro F, Terra SR, Paludo FJ, et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett. 2015;358:220&#x2013;231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25542083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XJ, Hayes JD, Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 2006;66:10983&#x2013;10994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17108137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 2008;135:1358&#x2013;1368. 68 e1&#x2013;68 e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18692501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009;15:3423&#x2013;3432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19417020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008;68:7975&#x2013;7984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3070411</ArticleId>
            <ArticleId IdType="pubmed">18829555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010;70:5486&#x2013;5496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2896449</ArticleId>
            <ArticleId IdType="pubmed">20530669</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27023064</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2016</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.</ArticleTitle>
        <Pagination>
          <StartPage>e0152465</StartPage>
          <MedlinePgn>e0152465</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0152465</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0152465</ELocationID>
        <Abstract>
          <AbstractText>The activation of Nrf2 has been demonstrated to play a crucial role in cancer cell resistance to different anticancer therapies. The inhibition of proteasome activity has been proposed as a chemosensitizing therapy but the activation of Nrf2 could reduce its efficacy. Using the highly chemoresistant neuroblastoma cells HTLA-230, here we show that the strong reduction in proteasome activity, obtained by using low concentration of bortezomib (BTZ, 2.5 nM), fails in reducing cell viability. BTZ treatment favours the binding of Nrf2 to the ARE sequences in the promoter regions of target genes such as heme oxygenase 1 (HO-1), the modulatory subunit of γ-glutamylcysteine ligase (GCLM) and the transporter for cysteine (x-CT), enabling their transcription. GSH level is also increased after BTZ treatment. The up-regulation of Nrf2 target genes is responsible for cell resistance since HO-1 silencing and GSH depletion synergistically decrease BTZ-treated cell viability. Moreover, cell exposure to all-trans-Retinoic acid (ATRA, 3 μM) reduces the binding of Nrf2 to the ARE sequences, decreases HO-1 induction and lowers GSH level increasing the efficacy of bortezomib. These data suggest the role of Nrf2, HO-1 and GSH as molecular targets to improve the efficacy of low doses of bortezomib in the treatment of malignant neuroblastoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Furfaro</LastName>
            <ForeName>A L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>Giannina Gaslini Institute, Via Gerolamo Gaslini 5, 16147, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piras</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Domenicotti</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fenoglio</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Biomedical Research, Department of Internal Medicine, University of Genoa, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Luigi</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Via Giuseppe La Masa 19, 20156, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salmona</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Via Giuseppe La Masa 19, 20156, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moretta</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio 4, 00165, Roma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marinari</LastName>
            <ForeName>U M</ForeName>
            <Initials>UM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pronzato</LastName>
            <ForeName>M A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Traverso</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nitti</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>03</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5688UTC01R</RegistryNumber>
          <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>69G8BD63PP</RegistryNumber>
          <NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.25.1</RegistryNumber>
          <NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.2.2</RegistryNumber>
          <NameOfSubstance UI="D005721">Glutamate-Cysteine Ligase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061745" MajorTopicYN="N">Antioxidant Response Elements</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005721" MajorTopicYN="N">Glutamate-Cysteine Ligase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27023064</ArticleId>
        <ArticleId IdType="pmc">PMC4811586</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0152465</ArticleId>
        <ArticleId IdType="pii">PONE-D-15-41334</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458(7239):780&#x2013;3. 10.1038/nature07733</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07733</ArticleId>
            <ArticleId IdType="pmc">PMC2778612</ArticleId>
            <ArticleId IdType="pubmed">19194462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013;12(12):931&#x2013;47. 10.1038/nrd4002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4002</ArticleId>
            <ArticleId IdType="pubmed">24287781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913 10.1155/2013/972913</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/972913</ArticleId>
            <ArticleId IdType="pmc">PMC3673338</ArticleId>
            <ArticleId IdType="pubmed">23766865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S, Khan AR, Gupta AK. Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol 2012;9(4):303&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22545423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 2007;9(12):2099&#x2013;117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2096718</ArticleId>
            <ArticleId IdType="pubmed">17822372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DS, Chae SW, Kim HR, Chae HJ. CO and bilirubin inhibit doxorubicin-induced cardiac cell death. Immunopharmacol Immunotoxicol 2009;31(1):64&#x2013;70. 10.1080/08923970802354762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08923970802354762</ArticleId>
            <ArticleId IdType="pubmed">18756386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 2013;1836(2):245&#x2013;54. 10.1016/j.bbcan.2013.07.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbcan.2013.07.002</ArticleId>
            <ArticleId IdType="pubmed">23891969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuhn P, Kunzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R, et al. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer 2009;8:37 10.1186/1476-4598-8-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-8-37</ArticleId>
            <ArticleId IdType="pmc">PMC2702301</ArticleId>
            <ArticleId IdType="pubmed">19508729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005;7(3&#x2013;4):385&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15706085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284(20):13291&#x2013;5. 10.1074/jbc.R900010200</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.R900010200</ArticleId>
            <ArticleId IdType="pmc">PMC2679427</ArticleId>
            <ArticleId IdType="pubmed">19182219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Numazawa S, Yoshida T. Nrf2-dependent gene expressions: a molecular toxicological aspect. J Toxicol Sci 2004;29(2):81&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15206576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13(11):1665&#x2013;78. 10.1089/ars.2010.3222</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2010.3222</ArticleId>
            <ArticleId IdType="pubmed">20446768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244(1):21&#x2013;6. 10.1016/j.taap.2009.06.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2009.06.016</ArticleId>
            <ArticleId IdType="pmc">PMC2837771</ArticleId>
            <ArticleId IdType="pubmed">19560482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 2013;85(6):705&#x2013;17. 10.1016/j.bcp.2012.11.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2012.11.016</ArticleId>
            <ArticleId IdType="pubmed">23219527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hohn TJ, Grune T. The proteasome and the degradation of oxidized proteins: Part III-Redox regulation of the proteasomal system. Redox Biol 2014;2:388&#x2013;94. 10.1016/j.redox.2013.12.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2013.12.029</ArticleId>
            <ArticleId IdType="pmc">PMC3926120</ArticleId>
            <ArticleId IdType="pubmed">24563857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998;77(3):448&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2151296</ArticleId>
            <ArticleId IdType="pubmed">9472642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9(17):6316&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14695130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joazeiro CA, Anderson KC, Hunter T. Proteasome inhibitor drugs on the rise. Cancer Res 2006;66(16):7840&#x2013;2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16861477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22(2):304&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15199612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15461622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lara PN Jr, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, et al. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol 2004;31(1 Suppl 1):40&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14981579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edelman MJ. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer 2005;7 Suppl 2:S64&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005;16(1):7&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15598929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010;16(16):4094&#x2013;104. 10.1158/1078-0432.CCR-09-2882</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-2882</ArticleId>
            <ArticleId IdType="pubmed">20682705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11(3):239&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3306611</ArticleId>
            <ArticleId IdType="pubmed">21247388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3(3):203&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12612655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008;7(2):135&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18771087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, et al. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res 2009;15(4):1199&#x2013;209. 10.1158/1078-0432.CCR-08-2477</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-2477</ArticleId>
            <ArticleId IdType="pubmed">19228726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8(8):2505&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12171876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev 2014;40(7):872&#x2013;82. 10.1016/j.ctrv.2014.04.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2014.04.004</ArticleId>
            <ArticleId IdType="pubmed">24830939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, et al. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. J Control Release;211:44&#x2013;52. 10.1016/j.jconrel.2015.05.286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2015.05.286</ArticleId>
            <ArticleId IdType="pubmed">26031842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furfaro AL, Piras S, Passalacqua M, Domenicotti C, Parodi A, Fenoglio D, et al. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib. Biochim Biophys Acta 2014;1842(4):613&#x2013;22. 10.1016/j.bbadis.2013.12.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2013.12.008</ArticleId>
            <ArticleId IdType="pubmed">24380881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005;24(29):4634&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15897905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 2008;57(4):541&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17786442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urru SA, Veglianese P, De Luigi A, Fumagalli E, Erba E, Gonella Diaza R, et al. A new fluorogenic peptide determines proteasome activity in single cells. J Med Chem 2010;53(20):7452&#x2013;60. 10.1021/jm100362x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm100362x</ArticleId>
            <ArticleId IdType="pubmed">20883027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furfaro AL, Macay JR, Marengo B, Nitti M, Parodi A, Fenoglio D, et al. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. Free Radic Biol Med 2012;52(2):488&#x2013;96. 10.1016/j.freeradbiomed.2011.11.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.11.007</ArticleId>
            <ArticleId IdType="pubmed">22142473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccirillo S, Filomeni G, Brune B, Rotilio G, Ciriolo MR. Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. J Biol Chem 2009;284(40):27721&#x2013;33. 10.1074/jbc.M109.014837</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.014837</ArticleId>
            <ArticleId IdType="pmc">PMC2785700</ArticleId>
            <ArticleId IdType="pubmed">19643729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fariss MW, Reed DJ. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol 1987;143:101&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3657520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furfaro AL, Nitti M, Marengo B, Domenicotti C, Cottalasso D, Marinari UM, et al. Impaired synthesis contributes to diabetes-induced decrease in liver glutathione. Int J Mol Med 2012;29(5):899&#x2013;905. 10.3892/ijmm.2012.915</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2012.915</ArticleId>
            <ArticleId IdType="pubmed">22344537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med 1999;27(9&#x2013;10):916&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10569624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asensi M, Sastre J, Pallardo FV, Lloret A, Lehner M, Garcia-de-la Asuncion J, et al. Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage. Methods Enzymol 1999;299:267&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9916205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson SA, White CC, Krejsa CM, Diaz D, Woods JS, Eaton DL, et al. Induction of glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) in the brains of adult female mice subchronically exposed to methylmercury. Toxicol Lett 1999;110(1&#x2013;2):1&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10593589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patriarca S, Furfaro AL, Domenicotti C, Odetti P, Cottalasso D, Marinari UM, et al. Supplementation with N-acetylcysteine and taurine failed to restore glutathione content in liver of streptozotocin-induced diabetics rats but protected from oxidative stress. Biochim Biophys Acta 2005;1741(1&#x2013;2):48&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15921899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, et al. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res 2007;67(7):3412&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17409452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher JM, et al. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol 2006;26(21):7942&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1636732</ArticleId>
            <ArticleId IdType="pubmed">16923960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan KP, Yang M, Ito S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol Pharmacol 2007;72(5):1380&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17724089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 2006;281(52):39776&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17077087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam J, Igarashi K, Immenschuh S, Shibahara S, Tyrrell RM. Regulation of heme oxygenase-1 gene transcription: recent advances and highlights from the International Conference (Uppsala, 2003) on Heme Oxygenase. Antioxid Redox Signal 2004;6(5):924&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15345152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XJ, Hayes JD, Henderson CJ, Wolf CR. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci U S A 2007;104(49):19589&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2148333</ArticleId>
            <ArticleId IdType="pubmed">18048326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itahana Y, Han R, Barbier S, Lei Z, Rozen S, Itahana K. The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene 2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24858040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SS, Seong S, Lim SH, Kim SY. Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma. Biochem Biophys Res Commun 2013;440(4):658&#x2013;63. 10.1016/j.bbrc.2013.09.120</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.09.120</ArticleId>
            <ArticleId IdType="pubmed">24113378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SS, Seong S, Lim SH, Kim SY. Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells. Anticancer Res 2013;33(11):4913&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24222129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003;278(24):21592&#x2013;600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12682069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S, et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 2009;83(2):354&#x2013;61. 10.1093/cvr/cvp107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvp107</ArticleId>
            <ArticleId IdType="pubmed">19351736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 2007;282(7):4364&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17158454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak MK, Huang B, Chang H, Kim JA, Kensler TW. Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. Life Sci 2007;80(26):2411&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17521679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Hur EG, Ryoo IG, Jung KA, Kwak J, Kwak MK. Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic beta-cells. Toxicol Appl Pharmacol 2012;264(3):431&#x2013;8. 10.1016/j.taap.2012.08.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2012.08.021</ArticleId>
            <ArticleId IdType="pubmed">22959925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pickering AM, Linder RA, Zhang H, Forman HJ, Davies KJ. Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress. J Biol Chem 2012;287(13):10021&#x2013;31. 10.1074/jbc.M111.277145</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.277145</ArticleId>
            <ArticleId IdType="pmc">PMC3323025</ArticleId>
            <ArticleId IdType="pubmed">22308036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na HK, Surh YJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 2014;67:353&#x2013;65. 10.1016/j.freeradbiomed.2013.10.819</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.10.819</ArticleId>
            <ArticleId IdType="pubmed">24200599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, et al. The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance. Oxid Med Cell Longev 2016;2016:1958174 10.1155/2016/1958174</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/1958174</ArticleId>
            <ArticleId IdType="pmc">PMC4677237</ArticleId>
            <ArticleId IdType="pubmed">26697129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue M, Momiji H, Rabbani N, Barker G, Bretschneider T, Shmygol A, et al. Frequency Modulated Translocational Oscillations of Nrf2 Mediate the Antioxidant Response Element Cytoprotective Transcriptional Response. Antioxid Redox Signal 2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4556091</ArticleId>
            <ArticleId IdType="pubmed">25178584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cullen SJ, Ponnappan S, Ponnappan U. Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. Mol Immunol 2009;47(2&#x2013;3):600&#x2013;5. 10.1016/j.molimm.2009.09.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2009.09.008</ArticleId>
            <ArticleId IdType="pmc">PMC2788002</ArticleId>
            <ArticleId IdType="pubmed">19800126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 1993;268(26):19675&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8103521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fraser JA, Kansagra P, Kotecki C, Saunders RD, McLellan LI. The modifier subunit of Drosophila glutamate-cysteine ligase regulates catalytic activity by covalent and noncovalent interactions and influences glutathione homeostasis in vivo. J Biol Chem 2003;278(47):46369&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12954617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009;30(1&#x2013;2):42&#x2013;59. 10.1016/j.mam.2008.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2008.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC2704241</ArticleId>
            <ArticleId IdType="pubmed">18601945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki I, Murakami S, Torigoe N, Kitamura Y, Asanuma M. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. J Neurochem 2016;136(1):194&#x2013;204. 10.1111/jnc.13405</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13405</ArticleId>
            <ArticleId IdType="pubmed">26485447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, et al. RXRalpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res 2013;73(10):3097&#x2013;108. 10.1158/0008-5472.CAN-12-3386</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3386</ArticleId>
            <ArticleId IdType="pubmed">23612120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valenzuela M, Glorieux C, Stockis J, Sid B, Sandoval JM, Felipe KB, et al. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br J Cancer 2014;111(5):874&#x2013;82. 10.1038/bjc.2014.380</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2014.380</ArticleId>
            <ArticleId IdType="pmc">PMC4150280</ArticleId>
            <ArticleId IdType="pubmed">25003661</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26883574</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <PubDate>
              <Year>2016</Year>
              <Month>Feb</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.</ArticleTitle>
        <Pagination>
          <StartPage>21164</StartPage>
          <MedlinePgn>21164</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">21164</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep21164</ELocationID>
        <Abstract>
          <AbstractText>Tamoxifen is the accepted therapy for patients with estrogen receptor-α (ERα)-positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes death from metastases. To improve breast cancer treatment it is vital to understand the mechanisms that result in tamoxifen resistance. This study shows that concentrations of tamoxifen and its metabolites, which accumulate in tumors of patients, killed both ERα-positive and ERα-negative breast cancer cells. This depended on oxidative damage and anti-oxidants rescued the cancer cells from tamoxifen-induced apoptosis. Breast cancer cells responded to tamoxifen-induced oxidation by increasing Nrf2 expression and subsequent activation of the anti-oxidant response element (ARE). This increased the transcription of anti-oxidant genes and multidrug resistance transporters. As a result, breast cancer cells are able to destroy or export toxic oxidation products leading to increased survival from tamoxifen-induced oxidative damage. These responses in cancer cells also occur in breast tumors of tamoxifen-treated mice. Additionally, high levels of expression of Nrf2, ABCC1, ABCC3 plus NAD(P)H dehydrogenase quinone-1 in breast tumors of patients at the time of diagnosis were prognostic of poor survival after tamoxifen therapy. Therefore, overcoming tamoxifen-induced activation of the ARE could increase the efficacy of tamoxifen in treating breast cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bekele</LastName>
            <ForeName>Raie T</ForeName>
            <Initials>RT</Initials>
            <AffiliationInfo>
              <Affiliation>Signal Transduction Research Group, Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venkatraman</LastName>
            <ForeName>Ganesh</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Signal Transduction Research Group, Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Rong-Zong</ForeName>
            <Initials>RZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Xiaoyun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Signal Transduction Research Group, Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mi</LastName>
            <ForeName>Si</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Agricultural, Food and Nutritional Science (Lipid Chemistry Group), University of Alberta, Edmonton, Alberta, T6G 2P5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benesch</LastName>
            <ForeName>Matthew G K</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Signal Transduction Research Group, Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mackey</LastName>
            <ForeName>John R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Godbout</LastName>
            <ForeName>Roseline</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curtis</LastName>
            <ForeName>Jonathan M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Agricultural, Food and Nutritional Science (Lipid Chemistry Group), University of Alberta, Edmonton, Alberta, T6G 2P5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McMullen</LastName>
            <ForeName>Todd P W</ForeName>
            <Initials>TP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Walter C Mackenzie Health Science Centre, University of Alberta, Edmonton, T6G 2R7, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brindley</LastName>
            <ForeName>David N</ForeName>
            <Initials>DN</Initials>
            <AffiliationInfo>
              <Affiliation>Signal Transduction Research Group, Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>02</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002518">Ceramides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020218" MajorTopicYN="N">Response Elements</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26883574</ArticleId>
        <ArticleId IdType="pmc">PMC4756695</ArticleId>
        <ArticleId IdType="doi">10.1038/srep21164</ArticleId>
        <ArticleId IdType="pii">srep21164</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jemal A. et al. Cancer statistics, 2006. CA Cancer J Clin 56, 106&#x2013;130, 10.3322/canjclin.56.2.106 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/canjclin.56.2.106</ArticleId>
            <ArticleId IdType="pubmed">16514137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists&#x2019; Collaborative Group. Lancet 351, 1451&#x2013;1467, S0140673697114234 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9605801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ring A. &amp; Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643&#x2013;658, 11/4/643 10.1677/erc.1.00776 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/erc.1.00776</ArticleId>
            <ArticleId IdType="pubmed">15613444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan V. C. Tamoxifen: a most unlikely pioneering medicine. Nature reviews. Drug discovery 2, 205&#x2013;213, 10.1038/nrd1031 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd1031</ArticleId>
            <ArticleId IdType="pubmed">12612646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaiyesimi I. A., Buzdar A. U., Decker D. A. &amp; Hortobagyi G. N. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13, 513&#x2013;529 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7844613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why? Ann Oncol 14, 1697&#x2013;1704 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14630672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brzozowski A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753&#x2013;758, 10.1038/39645 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/39645</ArticleId>
            <ArticleId IdType="pubmed">9338790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiau A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927&#x2013;937, S0092-8674(00)81717-1 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9875847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kushner P. J. et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74, 311&#x2013;317, S0960-0760(00)00108-4 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11162939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan V. C., Collins M. M., Rowsby L. &amp; Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75, 305&#x2013;316 (1977).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">591813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen K. E., Clark E. R. &amp; Jordan V. C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 71, 83&#x2013;91 (1980).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2044398</ArticleId>
            <ArticleId IdType="pubmed">7470748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuiper G. G. J. M. et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863&#x2013;870, 10.1210/En.138.3.863 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/En.138.3.863</ArticleId>
            <ArticleId IdType="pubmed">9048584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas C. &amp; Gustafsson J. A. The different roles of ER subtypes in cancer biology and therapy. Nature Reviews Cancer 11, 597&#x2013;608, 10.1038/Nrc3093 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/Nrc3093</ArticleId>
            <ArticleId IdType="pubmed">21779010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koehler K. F., Helguero L. A., Haldosen L. A., Warner M. &amp; Gustafsson J. A. Reflections on the discovery and significance of estrogen receptor beta. Endocrine Reviews 26, 465&#x2013;478, 10.1210/Er.2004-0027 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/Er.2004-0027</ArticleId>
            <ArticleId IdType="pubmed">15857973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Improta-Brears T. et al. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci USA 96, 4686&#x2013;4691 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC16393</ArticleId>
            <ArticleId IdType="pubmed">10200323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simoncini T. et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538&#x2013;541, 10.1038/35035131 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35035131</ArticleId>
            <ArticleId IdType="pmc">PMC2670482</ArticleId>
            <ArticleId IdType="pubmed">11029009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aronica S. M., Kraus W. L. &amp; Katzenellenbogen B. S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91, 8517&#x2013;8521 (1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC44637</ArticleId>
            <ArticleId IdType="pubmed">8078914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prossnitz E. R., Arterburn J. B. &amp; Sklar L. A. GPR30: A G protein-coupled receptor for estrogen. Molecular and Cellular Endocrinology 265, 138&#x2013;142, 10.1016/J.Mce.2006.12.010 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.Mce.2006.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC1847610</ArticleId>
            <ArticleId IdType="pubmed">17222505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peto R. Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast-Cancer - an Overview of 61 Randomized Trials among 28,896 Women. Hormone Research 32, 165&#x2013;165, 10.1159/000181336 (1988).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000181336</ArticleId>
            <ArticleId IdType="pubmed">3205265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher B. et al. A Randomized Clinical-Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast-Cancer Who Have Estrogen-Receptor Positive Tumors. New England Journal of Medicine 320, 479&#x2013;484, 10.1056/Nejm198902233200802 (1989).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/Nejm198902233200802</ArticleId>
            <ArticleId IdType="pubmed">2644532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowsett M. et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17, 818&#x2013;826, 10.1093/annonc/mdl016 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdl016</ArticleId>
            <ArticleId IdType="pubmed">16497822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldenberg G. J. &amp; Froese E. K. Drug and Hormone Sensitivity of Estrogen Receptor-Positive and Receptor-Negative Human-Breast Cancer-Cells Invitro. Cancer Research 42, 5147&#x2013;5151 (1982).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7139616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gelmann E. P. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst 88, 224&#x2013;226 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8613997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gundimeda U., Chen Z. H. &amp; Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271, 13504&#x2013;13514 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8662863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horgan K., Cooke E., Hallett M. B. &amp; Mansel R. E. Inhibition of Protein-Kinase-C Mediated Signal Transduction by Tamoxifen - Importance for Antitumor-Activity. Biochemical Pharmacology 35, 4463&#x2013;4465, 10.1016/0006-2952(86)90764-1 (1986).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-2952(86)90764-1</ArticleId>
            <ArticleId IdType="pubmed">3790165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry R. R., Kang Y. &amp; Greaves B. R. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72, 1441&#x2013;1446 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2034073</ArticleId>
            <ArticleId IdType="pubmed">8519657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y., Cortina R. &amp; Perry R. R. Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. Journal of the National Cancer Institute 88, 279&#x2013;284, 10.1093/Jnci/88.5.279 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/Jnci/88.5.279</ArticleId>
            <ArticleId IdType="pubmed">8614006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor C. M., Blanchard B. &amp; Zava D. T. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44, 1409&#x2013;1414 (1984).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6704959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandlekar S., Hebbar V., Christov K. &amp; Kong A. N. T. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: Activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Research 60, 6601&#x2013;6606 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11118041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandlekar S., Yu R., Tan T. H. &amp; Kong A. N. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60, 5995&#x2013;6000 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11085519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beguerie J. R., Xingzhong J. &amp; Valdez R. P. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis. International Journal of Dermatology 49, 1194&#x2013;1202, 10.1111/J.1365-4632.2010.04529.X (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/J.1365-4632.2010.04529.X</ArticleId>
            <ArticleId IdType="pubmed">20883410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couldwell W. T. et al. Clinical and Radiographic Response in a Minority of Patients with Recurrent Malignant Gliomas Treated with High-Dose Tamoxifen. Neurosurgery 32, 485&#x2013;490 (1993).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8384328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saji S., Hirose M. &amp; Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 56 Suppl 1, 21&#x2013;26, 10.1007/s00280-005-0107-3 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-005-0107-3</ArticleId>
            <ArticleId IdType="pubmed">16273360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moi P., Chan K., Asunis I., Cao A. &amp; Kan Y. W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91, 9926&#x2013;9930 (1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC44930</ArticleId>
            <ArticleId IdType="pubmed">7937919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venugopal R. &amp; Jaiswal A. K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93, 14960&#x2013;14965 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC26245</ArticleId>
            <ArticleId IdType="pubmed">8962164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T. et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135, 1358&#x2013;1368, 1368 e1351-1354, 10.1053/j.gastro.2008.06.082 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2008.06.082</ArticleId>
            <ArticleId IdType="pubmed">18692501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A. et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68, 7975&#x2013;7984, 10.1158/0008-5472.CAN-08-1401 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-1401</ArticleId>
            <ArticleId IdType="pmc">PMC3070411</ArticleId>
            <ArticleId IdType="pubmed">18829555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P. et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9, 336&#x2013;346, 10.1158/1535-7163.MCT-09-0589 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-0589</ArticleId>
            <ArticleId IdType="pmc">PMC2821808</ArticleId>
            <ArticleId IdType="pubmed">20124447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kisanga E. R. et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10, 2336&#x2013;2343 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15073109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fromson J. M., Pearson S. &amp; Bramah S. The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 3, 711&#x2013;714, 10.3109/00498257309151595 (1973).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00498257309151595</ArticleId>
            <ArticleId IdType="pubmed">4783632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson S. P., Langan-Fahey S. M., Johnson D. A. &amp; Jordan V. C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19, 36&#x2013;43 (1991).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1673419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreier S. M. et al. Hydrogen sulfide scavenges the cytotoxic lipid oxidation product 4-HNE. Neurotoxicity research 17, 249&#x2013;256, 10.1007/s12640-009-9099-9 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12640-009-9099-9</ArticleId>
            <ArticleId IdType="pubmed">19680736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson D. W. et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37&#x2013;43, 10.1038/376037a0 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/376037a0</ArticleId>
            <ArticleId IdType="pubmed">7596430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y., Zhao S. &amp; Song J. Caspase-dependent apoptosis and -independent poly(ADP-ribose) polymerase cleavage induced by transforming growth factor beta1. Int J Biochem Cell Biol 36, 223&#x2013;234 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14643888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westwick J. K., Bielawska A. E., Dbaibo G., Hannun Y. A. &amp; Brenner D. A. Ceramide activates the stress-activated protein kinases. J Biol Chem 270, 22689&#x2013;22692 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7559390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hetz C. A. et al. Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase. J Cell Sci 115, 4671&#x2013;4683 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12415011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parra V. et al. Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc Res 77, 387&#x2013;397, 10.1093/cvr/cvm029 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvm029</ArticleId>
            <ArticleId IdType="pubmed">18006463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu S. &amp; Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 17, 3277&#x2013;3285, 10.1038/sj.onc.1202570 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1202570</ArticleId>
            <ArticleId IdType="pubmed">9916990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman G. et al. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J, 10.1096/fj.14-262659 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.14-262659</ArticleId>
            <ArticleId IdType="pubmed">25398768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu R. Z. et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol 178, 997&#x2013;1008, 10.1016/j.ajpath.2010.11.075 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2010.11.075</ArticleId>
            <ArticleId IdType="pmc">PMC3070589</ArticleId>
            <ArticleId IdType="pubmed">21356353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Q. &amp; Bodell W. J. Production of 8-hydroxy-2&#x2032;-deoxguanosine in DNA by microsomal activation of tamoxifen and 4-hydroxytamoxifen. Carcinogenesis 17, 1747&#x2013;1750 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8761436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiff R. et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92, 1926&#x2013;1934 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11106684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y. S., Kang Y. S., Lee S. H. &amp; Kim J. A. Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 7, 925&#x2013;932, 10.1038/sj.cdd.4400717 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4400717</ArticleId>
            <ArticleId IdType="pubmed">11279538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S. K. et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 45, 537&#x2013;546, 10.1016/j.freeradbiomed.2008.05.011 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2008.05.011</ArticleId>
            <ArticleId IdType="pubmed">18539158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlini C. et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79, 257&#x2013;263, 10.1038/sj.bjc.6690042 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6690042</ArticleId>
            <ArticleId IdType="pmc">PMC2362195</ArticleId>
            <ArticleId IdType="pubmed">9888466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katzenellenbogen B. S., Miller M. A., Mullick A. &amp; Sheen Y. Y. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res Treat 5, 231&#x2013;243 (1985).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4027393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishitoh H. et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 2, 389&#x2013;395 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9774977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santana P. et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86, 189&#x2013;199 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8706124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y. et al. Involvement of the acid sphingomyelinase pathway in uva-induced apoptosis. J Biol Chem 276, 11775&#x2013;11782, 10.1074/jbc.M006000200 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M006000200</ArticleId>
            <ArticleId IdType="pmc">PMC2621016</ArticleId>
            <ArticleId IdType="pubmed">11278294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B. &amp; Hannun Y. A. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272, 16281&#x2013;16287 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9195931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janicke R. U., Sprengart M. L., Wati M. R. &amp; Porter A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273, 9357&#x2013;9360 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9545256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C. Y. et al. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Res 16, 431, 10.1186/s13058-014-0431-9 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-014-0431-9</ArticleId>
            <ArticleId IdType="pmc">PMC4303112</ArticleId>
            <ArticleId IdType="pubmed">25228280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W. et al. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ 10, 772&#x2013;781, 10.1038/sj.cdd.4401238 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401238</ArticleId>
            <ArticleId IdType="pubmed">12815460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renes J. et al. Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J 350 Pt 2, 555&#x2013;561 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1221284</ArticleId>
            <ArticleId IdType="pubmed">10947971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi H. K., Yang J. W., Roh S. H., Han C. Y. &amp; Kang K. W. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 14, 293&#x2013;303, 10.1677/ERC-06-0016 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/ERC-06-0016</ArticleId>
            <ArticleId IdType="pubmed">17639045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiyotani K. et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28, 1287&#x2013;1293, 10.1200/JCO.2009.25.7246 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.25.7246</ArticleId>
            <ArticleId IdType="pmc">PMC4872305</ArticleId>
            <ArticleId IdType="pubmed">20124171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunicka T. et al. Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer. PLoS One 9, e101740, 10.1371/journal.pone.0101740 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0101740</ArticleId>
            <ArticleId IdType="pmc">PMC4117604</ArticleId>
            <ArticleId IdType="pubmed">25078270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada A. et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137, 773&#x2013;782, 10.1007/s10549-012-2398-5 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-012-2398-5</ArticleId>
            <ArticleId IdType="pmc">PMC3560367</ArticleId>
            <ArticleId IdType="pubmed">23288347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cronin-Fenton D. P., Damkier P. &amp; Lash T. L. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol 10, 107&#x2013;122, 10.2217/fon.13.168 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon.13.168</ArticleId>
            <ArticleId IdType="pmc">PMC4319217</ArticleId>
            <ArticleId IdType="pubmed">24328412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paulusma C. C. et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271, 1126&#x2013;1128 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8599091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leslie E. M., Deeley R. G. &amp; Cole S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204, 216&#x2013;237, 10.1016/j.taap.2004.10.012 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2004.10.012</ArticleId>
            <ArticleId IdType="pubmed">15845415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callaghan R. &amp; Higgins C. F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71, 294&#x2013;299 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2033580</ArticleId>
            <ArticleId IdType="pubmed">7841043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sareddy G. R. et al. Therapeutic significance of estrogen receptor beta agonists in gliomas. Mol Cancer Ther 11, 1174&#x2013;1182, 10.1158/1535-7163.MCT-11-0960 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-11-0960</ArticleId>
            <ArticleId IdType="pmc">PMC3721065</ArticleId>
            <ArticleId IdType="pubmed">22442308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montano M. M., Jaiswal A. K. &amp; Katzenellenbogen B. S. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. J Biol Chem 273, 25443&#x2013;25449 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9738013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samadi N., Gaetano C., Goping I. S. &amp; Brindley D. N. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28, 1028&#x2013;1039, onc2008442 10.1038/onc.2008442 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2008</ArticleId>
            <ArticleId IdType="pubmed">19079345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe K. et al. Lysophosphatidic acid receptor-3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells. Molecular carcinogenesis 52, 247&#x2013;254, 10.1002/mc.21851 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.21851</ArticleId>
            <ArticleId IdType="pubmed">22161812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benesch M. G. et al. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J 28, 2655&#x2013;2666, 10.1096/fj.13-248641 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.13-248641</ArticleId>
            <ArticleId IdType="pubmed">24599971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldshmit Y. et al. Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes. Am J Pathol 181, 978&#x2013;992, 10.1016/j.ajpath.2012.06.007 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2012.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC3432439</ArticleId>
            <ArticleId IdType="pubmed">22819724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren D. et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci USA 108, 1433&#x2013;1438, 10.1073/pnas.1014275108 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1014275108</ArticleId>
            <ArticleId IdType="pmc">PMC3029730</ArticleId>
            <ArticleId IdType="pubmed">21205897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arlt A. et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32, 4825&#x2013;4835, 10.1038/onc.2012.493 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.493</ArticleId>
            <ArticleId IdType="pubmed">23108405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang X. et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 50, 1599&#x2013;1609, 10.1016/j.freeradbiomed.2011.03.008 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.03.008</ArticleId>
            <ArticleId IdType="pubmed">21402146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X. J., Hayes J. D. &amp; Wolf C. R. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res 66, 10983&#x2013;10994, 10.1158/0008-5472.CAN-06-2298 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-2298</ArticleId>
            <ArticleId IdType="pubmed">17108137</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25523186</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-3169</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>233</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Mar</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxicology letters</Title>
          <ISOAbbreviation>Toxicol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Changes in Caco-2 cells transcriptome profiles upon exposure to gold nanoparticles.</ArticleTitle>
        <Pagination>
          <StartPage>187</StartPage>
          <EndPage>199</EndPage>
          <MedlinePgn>187-99</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2014.12.008</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-4274(14)01515-X</ELocationID>
        <Abstract>
          <AbstractText>Higher efficacy and safety of nano gold therapeutics require examination of cellular responses to gold nanoparticles (AuNPs). In this work we compared cellular uptake, cytotoxicity and RNA expression patterns induced in Caco-2 cells exposed to AuNP (5 and 30nm). Cellular internalization was dose and time-dependent for both AuNPs. The toxicity was observed by colony forming efficiency (CFE) and not by Trypan blue assay, and exclusively for 5nm AuNPs, starting at the concentration of 200μM (24 and 72h of exposure). The most pronounced changes in gene expression (Agilent microarrays) were detected at 72h (300μM) of exposure to AuNPs (5nm). The biological processes affected by smaller AuNPs were: RNA/zinc ion/transition metal ion binding (decreased), cadmium/copper ion binding and glutathione metabolism (increased). Some Nrf2 responsive genes (several metallothioneins, HMOX, G6PD, OSGIN1 and GPX2) were highly up regulated. Members of the selenoproteins were also differentially expressed. Our findings indicate that exposure to high concentration of AuNPs (5nm) induces metal exposure, oxidative stress signaling pathways, and might influence selenium homeostasis. Some of detected cellular responses might be explored as potential enhancers of anti-cancer properties of AuNPs based nanomedicines.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bajak</LastName>
            <ForeName>Edyta</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: edyta.bajak@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fabbri</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy; Department of Clinical and Experimental Medicine, University of Insubria, via J. Dunant, 5, 21100 Varese, Italy. Electronic address: marco.fabbri@uninsubria.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ponti</LastName>
            <ForeName>Jessica</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: jessica.ponti@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gioria</LastName>
            <ForeName>Sabrina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: sabrina.gioria@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ojea-Jiménez</LastName>
            <ForeName>Isaac</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: isaac.ojea-jimenez@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collotta</LastName>
            <ForeName>Angelo</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, JRC, IHCP, Molecular Biology and Genomics (MBG) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: angelo.collotta@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mariani</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: valentina.mariani@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gilliland</LastName>
            <ForeName>Douglas</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: douglas.gillland@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rossi</LastName>
            <ForeName>François</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), Nanobiosciences (NBS) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: francois.rossi@jrc.ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gribaldo</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>European Commission, JRC, IHCP, Chemical Assessment and Testing (CAT) Unit, via E. Fermi 2749, 21027 Ispra (VA), Italy. Electronic address: laura.gribaldo@ec.europa.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Toxicol Lett</MedlineTA>
        <NlmUniqueID>7709027</NlmUniqueID>
        <ISSNLinking>0378-4274</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>7440-57-5</RegistryNumber>
          <NameOfSubstance UI="D006046">Gold</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018938" MajorTopicYN="N">Caco-2 Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006046" MajorTopicYN="N">Gold</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AuNPs uptake</Keyword>
        <Keyword MajorTopicYN="N">Cellular signaling</Keyword>
        <Keyword MajorTopicYN="N">Stress responses</Keyword>
        <Keyword MajorTopicYN="N">Transcriptomics</Keyword>
        <Keyword MajorTopicYN="N">qPCR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25523186</ArticleId>
        <ArticleId IdType="doi">10.1016/j.toxlet.2014.12.008</ArticleId>
        <ArticleId IdType="pii">S0378-4274(14)01515-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24763052</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Apr</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.</ArticleTitle>
        <Pagination>
          <StartPage>e1195</StartPage>
          <MedlinePgn>e1195</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/cddis.2014.157</ELocationID>
        <Abstract>
          <AbstractText>The epigenetic sensor BRD4 (bromodomain protein 4) is a potent target for anti-cancer therapies. To study the transcriptional impact of BRD4 in cancer, we generated an expression signature of BRD4 knockdown cells and found oxidative stress response genes significantly enriched. We integrated the RNA-Seq results with DNA-binding sites of BRD4 generated by chromatin immunoprecipitations, correlated these with gene expressions from human prostate cancers and identified 21 top BRD4 candidate genes among which the oxidative stress pathway genes KEAP1, SESN3 and HDAC6 are represented. Knock down of BRD4 or treatment with the BRD4 inhibitor JQ1 resulted in decreased reactive oxygen species (ROS) production and increased cell viability under H2O2 exposure. Consistently, a deregulation of BRD4 diminished the KEAP1/NRF2 axis and led to a disturbed regulation of the inducible heme oxygenase 1 (HMOX1). Without exogenous stress induction, we also found BRD4 directly targeting the HMOX1 promoter over the SP1-binding sites. Our findings provide insight into the transcriptional regulatory network of BRD4 and highlight BRD4 as signal transducer of the cellular response to oxidative stress.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hussong</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany [2] Department of Biology, Chemistry and Pharmacy, Free University, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Börno</LastName>
            <ForeName>S T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kerick</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wunderlich</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franz</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany [2] Department of Biology, Chemistry and Pharmacy, Free University, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sültmann</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Timmermann</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Next Generation Sequencing Group, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lehrach</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirsch-Kauffmann</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schweiger</LastName>
            <ForeName>M R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany [2] Cologne Center for Genomics, University of Cologne, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>04</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C561695">(+)-JQ1 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001381">Azepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C441289">BRD4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C431364">KEAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011524">Protoporphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63AAN3JDZE</RegistryNumber>
          <NameOfSubstance UI="C007095">cobaltiprotoporphyrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059372" MajorTopicYN="N">Nucleotide Motifs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011524" MajorTopicYN="N">Protoporphyrins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24763052</ArticleId>
        <ArticleId IdType="pmc">PMC4001311</ArticleId>
        <ArticleId IdType="doi">10.1038/cddis.2014.157</ArticleId>
        <ArticleId IdType="pii">cddis2014157</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991;10:2247&#x2013;2258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC452914</ArticleId>
            <ArticleId IdType="pubmed">2065663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003;278:21592&#x2013;21600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12682069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam J, Cook JL. Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Curr Pharm Des. 2003;9:2499&#x2013;2511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14529549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi A, Ohta T, Yamamoto M. Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol. 2004;378:273&#x2013;286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15038975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh K, Wakabayashi N, Katoh Y, Ishii T, O'Connor T, Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells. 2003;8:379&#x2013;391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12653965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23:8137&#x2013;8151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC262403</ArticleId>
            <ArticleId IdType="pubmed">14585973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda H, Serria MS, Kakizaki I, Hatayama I, Satoh K, Tsuchida S, et al. Activation of mouse Pi-class glutathione S-transferase gene by Nrf2(NF-E2-related factor 2) and androgen. Biochem J. 2002;364 (Pt 2:563&#x2013;570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1222602</ArticleId>
            <ArticleId IdType="pubmed">12023900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, et al. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 2001;61:3299&#x2013;3307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11309284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem. 1999;274:26071&#x2013;26078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10473555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3:e420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1584412</ArticleId>
            <ArticleId IdType="pubmed">17020408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008;68:1303&#x2013;1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18316592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research N Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519&#x2013;525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3466113</ArticleId>
            <ArticleId IdType="pubmed">22960745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweiger MR, You J, Howley PM. Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol. 2006;80:4276&#x2013;4285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1472042</ArticleId>
            <ArticleId IdType="pubmed">16611886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19:523&#x2013;534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16109376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem. 2007;282:13141&#x2013;13145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17329240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ, et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012;287:43137&#x2013;43155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3522308</ArticleId>
            <ArticleId IdType="pubmed">23086925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci USA. 2012;109:6927&#x2013;6932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3345009</ArticleId>
            <ArticleId IdType="pubmed">22509028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320&#x2013;334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3760967</ArticleId>
            <ArticleId IdType="pubmed">23582323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307&#x2013;319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3653129</ArticleId>
            <ArticleId IdType="pubmed">23582322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA. 2012;109:19408&#x2013;19413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3511085</ArticleId>
            <ArticleId IdType="pubmed">23129625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524&#x2013;528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3328300</ArticleId>
            <ArticleId IdType="pubmed">21814200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478:529&#x2013;533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3679520</ArticleId>
            <ArticleId IdType="pubmed">21964340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, et al. BRD4 sustains proliferation and represents a new target for epigenetic therapy in melanoma. Cancer Res. 2013;73:6264&#x2013;6276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254777</ArticleId>
            <ArticleId IdType="pubmed">23950209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011;11:507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3259213</ArticleId>
            <ArticleId IdType="pubmed">22142399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology. 2012;60:943&#x2013;952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22348534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karve TM, Rosen EM. B-cell translocation gene 2 (BTG2) stimulates cellular antioxidant defenses through the antioxidant transcription factor NFE2L2 in human mammary epithelial cells. J Biol Chem. 2012;287:31503&#x2013;31514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3438983</ArticleId>
            <ArticleId IdType="pubmed">22493435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med. 2005;202:47&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212893</ArticleId>
            <ArticleId IdType="pubmed">15998787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam J, Cai J, Smith A. Isolation and characterization of the mouse heme oxygenase-1 gene. Distal 5' sequences are required for induction by heme or heavy metals. J Biol Chem. 1994;269:1001&#x2013;1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8288554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067&#x2013;1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3010259</ArticleId>
            <ArticleId IdType="pubmed">20871596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009;29:1375&#x2013;1387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2643823</ArticleId>
            <ArticleId IdType="pubmed">19103749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009;37 (Web Server issue:W202&#x2013;W208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2703892</ArticleId>
            <ArticleId IdType="pubmed">19458158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel MC, Debrosse M, Smith M, Dey A, Huynh W, Sarai N, et al. BRD4 coordinates recruitment of pause-release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon stimulated genes. Mol Cell Biol. 2013;33:2497&#x2013;2507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3700095</ArticleId>
            <ArticleId IdType="pubmed">23589332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fowler T, Sen R, Roy AL. Regulation of primary response genes. Mol Cell. 2011;44:348&#x2013;360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3212756</ArticleId>
            <ArticleId IdType="pubmed">22055182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 2009;138:129&#x2013;145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828818</ArticleId>
            <ArticleId IdType="pubmed">19596240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, et al. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA. 2008;105:6380&#x2013;6385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2359777</ArticleId>
            <ArticleId IdType="pubmed">18427120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez RM, Huidobro C, Urdinguio RG, Mangas C, Soldevilla B, Dominguez G, et al. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med (Berl) 2012;90:587&#x2013;595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22120039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsarraj J, Walker RC, Webster JD, Geiger TR, Crawford NP, Simpson RM, et al. Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion. Cancer Res. 2011;71:3121&#x2013;3131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3078189</ArticleId>
            <ArticleId IdType="pubmed">21389092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winyard PG, Moody CJ, Jacob C. Oxidative activation of antioxidant defence. Trends Biochem Sci. 2005;30:453&#x2013;461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15996871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruppitsch W, Meisslitzer C, Weirich-Schwaiger H, Klocker H, Scheidereit C, Schweiger M, et al. The role of oxygen metabolism for the pathological phenotype of Fanconi anemia. Hum Genet. 1997;99:710&#x2013;719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9187662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kontou M, Hirsch-Kauffmann M, Schweiger M. Impaired synthesis of heme oxygenase-1 in Fanconi anemia cells can be rescued by transfection of Fanconi wild-type cDNA. Biol Chem. 2008;389:1327&#x2013;1332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18713020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 2008;105:13568&#x2013;13573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2533230</ArticleId>
            <ArticleId IdType="pubmed">18757741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimm H, Kim S, Jee SH. The independent effects of cigarette smoking, alcohol consumption, and serum aspartate aminotransferase on the alanine aminotransferase ratio in korean men for the risk for esophageal cancer. Yonsei Med J. 2010;51:310&#x2013;317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2852784</ArticleId>
            <ArticleId IdType="pubmed">20376881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011;16:123&#x2013;140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21251164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, et al. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics. 2013;8:105&#x2013;112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549873</ArticleId>
            <ArticleId IdType="pubmed">23249627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer. 2012;12:66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3296656</ArticleId>
            <ArticleId IdType="pubmed">22325485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muscarella LA, Barbano R, D'Angelo V, Copetti M, Coco M, Balsamo T, et al. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics. 2011;6:317&#x2013;325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3092680</ArticleId>
            <ArticleId IdType="pubmed">21173573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106&#x2013;109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3404470</ArticleId>
            <ArticleId IdType="pubmed">21734707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood. 2008;111:3793&#x2013;3801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18202225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget. 2013;4:2419&#x2013;2429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3926837</ArticleId>
            <ArticleId IdType="pubmed">24293458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, et al. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009;69:8017&#x2013;8024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19808972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119&#x2013;1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5415086</ArticleId>
            <ArticleId IdType="pubmed">21068722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweiger MR, Ottinger M, You J, Howley PM. Brd4-independent transcriptional repression function of the papillomavirus e2 proteins. J Virol. 2007;81:9612&#x2013;9622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045424</ArticleId>
            <ArticleId IdType="pubmed">17626100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You J, Croyle JL, Nishimura A, Ozato K, Howley PM. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell. 2004;117:349&#x2013;360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15109495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahl JA, Collas P. A quick and quantitative chromatin immunoprecipitation assay for small cell samples. Front Biosci. 2007;12:4925&#x2013;4931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17569620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mochizuki K, Nishiyama A, Jang MK, Dey A, Ghosh A, Tamura T, et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem. 2008;283:9040&#x2013;9048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2431025</ArticleId>
            <ArticleId IdType="pubmed">18223296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207&#x2013;210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC99122</ArticleId>
            <ArticleId IdType="pubmed">11752295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2592715</ArticleId>
            <ArticleId IdType="pubmed">18798982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmon-Divon M, Dvinge H, Tammoja K, Bertone P. PeakAnalyzer: genome-wide annotation of chromatin binding and modification loci. BMC Bioinformatics. 2010;11:415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2923140</ArticleId>
            <ArticleId IdType="pubmed">20691053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012;2:1024&#x2013;1035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22930729</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22684019</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>12</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>53</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Aug</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Free radical biology &amp; medicine</Title>
          <ISOAbbreviation>Free Radic Biol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.</ArticleTitle>
        <Pagination>
          <StartPage>807</StartPage>
          <EndPage>816</EndPage>
          <MedlinePgn>807-16</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.freeradbiomed.2012.05.038</ELocationID>
        <Abstract>
          <AbstractText>Radiotherapy and chemotherapeutic agents can effectively induce apoptosis through generation of reactive oxygen species (ROS). Cancer cells frequently express high levels of ROS-scavenging enzymes, which confer resistance to ROS-mediated cell death. Keap1 (Kelch-like ECH-associated protein 1) sequesters and promotes the degradation of the antioxidant response element-binding transcription factor Nrf2 (nuclear factor erythroid-2-related factor 2). In non-small-cell lung cancer (NSCLC) cell lines and NSCLC patients, Keap1 is often present as a biallelic mutant that results in constitutive activation of Nrf2 function, which contributes to cytoprotection against oxidative stress and xenobiotics. To identify small molecules that inhibit antioxidant responses and increase apoptotic death after radiotherapy, we screened a chemical library containing 8000 synthetic compounds using a cell-based luciferase assay system. 4-(2-Cyclohexylethoxy)aniline (IM3829) inhibited the increase in Nrf2-binding activity and expression of the Nrf2 target genes induced by treatment with tertiary butylhydroquinone or radiation. Combined treatment with IM3829 and radiation significantly inhibited clonogenic survival of H1299, A549, and H460 lung cancer cells. IM3829 significantly increased ROS accumulation in irradiated cells compared with cells exposed to radiation alone and led to apoptotic cell death, as confirmed by caspase-3 and PARP cleavage. In mice bearing H1299 or A549 lung cancer xenografts, IM3829 together with radiation inhibited tumor growth more effectively than radiation alone. Our findings suggest that IM3829 could be a promising radiosensitizer in lung cancer patients, particularly those with high expression of Nrf2.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Saelooom</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Cancer Research, Korea Institute of Radiological &amp; Medical Sciences, Seoul 139-706, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lim</LastName>
            <ForeName>Min-Jin</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Mi-Hyoung</ForeName>
            <Initials>MH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Chi-Ho</ForeName>
            <Initials>CH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yun</LastName>
            <ForeName>Yeon-Sook</ForeName>
            <Initials>YS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahn</LastName>
            <ForeName>Jiyeon</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Jie-Young</ForeName>
            <Initials>JY</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>06</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Free Radic Biol Med</MedlineTA>
        <NlmUniqueID>8709159</NlmUniqueID>
        <ISSNLinking>0891-5849</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C576912">4-(2-cyclohexylethoxy)aniline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006873">Hydroquinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011838">Radiation-Sensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>C12674942B</RegistryNumber>
          <NameOfSubstance UI="C018855">2-tert-butylhydroquinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.13.12.5</RegistryNumber>
          <NameOfSubstance UI="D049410">Luciferases, Renilla</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="C496541">HMOX1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061745" MajorTopicYN="N">Antioxidant Response Elements</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006873" MajorTopicYN="N">Hydroquinones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049410" MajorTopicYN="N">Luciferases, Renilla</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011838" MajorTopicYN="N">Radiation-Sensitizing Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>5</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>5</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22684019</ArticleId>
        <ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.05.038</ArticleId>
        <ArticleId IdType="pii">S0891-5849(12)00295-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19548348</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>07</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0893-228X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>21</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Chemical research in toxicology</Title>
          <ISOAbbreviation>Chem Res Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Genome-wide transcriptional responses to acrolein.</ArticleTitle>
        <Pagination>
          <StartPage>2245</StartPage>
          <EndPage>2256</EndPage>
          <MedlinePgn>2245-56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/tx8001934</ELocationID>
        <Abstract>
          <AbstractText>The lipid peroxidation product and environmental pollutant acrolein participates in many diseases. Because of its formation during tobacco combustion, its role in various smoking-related respiratory conditions including lung cancer has received increasing attention. As a reactive electrophile, acrolein seems likely to disrupt many biochemical pathways, but these are poorly characterized on a genome-wide basis. This study used microarrays to study short-term transcriptional responses of A549 human lung cells to acrolein, with cells exposed to 100 microM acrolein for 1, 2, or 4 h prior to RNA extraction and transcription profiling. Major pathways dysregulated by acrolein included those involved in apoptosis, cell cycle control, transcription, cell signaling, and protein biosynthesis. Although HMOX1 is a widely used marker of transcriptional responses to acrolein, this gene was the sole upregulated member of the Nrf2-driven family of antioxidant response genes. Transcript levels of several members of the metallothionein class of cytoprotective metal-chelating proteins decreased strongly in response to acrolein. Other novel findings included strong and persistent upregulation of several members of the early growth response (EGR) class of zinc finger transcription factors. Real-time PCR and Western blotting confirmed strong upregulation of a key member of this family (EGR-2), the DNA damage response gene GADD45beta, the heat shock response participant Hsp70, and also HMOX1. Consistent with changes in Nur77 mRNA levels during the microarray study, Western blotting confirmed strong Nur77 induction at the protein level, raising the possibility that this death-inducing protein contributes to the loss of cell viability during acrolein exposure. Collectively, the transcriptional response to acrolein is complex and dynamic, with future work needed to determine whether acrolein-responsive genes identified in this study contribute to cell and tissue injury in the smoke-exposed lung.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>Colin A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology and Anaesthesiology Unit, School of Medicine and Pharmacology, The University of Western Australia, Perth WA 6009, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burcham</LastName>
            <ForeName>Philip C</ForeName>
            <Initials>PC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Chem Res Toxicol</MedlineTA>
        <NlmUniqueID>8807448</NlmUniqueID>
        <ISSNLinking>0893-228X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497326">EGR2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051767">Early Growth Response Protein 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004785">Environmental Pollutants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C086470">GADD45B protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C539821">NR4A1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011987">Receptors, Steroid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7864XYD3JJ</RegistryNumber>
          <NameOfSubstance UI="D000171">Acrolein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="C496541">HMOX1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000171" MajorTopicYN="N">Acrolein</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000943" MajorTopicYN="N">Antigens, Differentiation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053938" MajorTopicYN="N">DNA Fragmentation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051767" MajorTopicYN="N">Early Growth Response Protein 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004785" MajorTopicYN="N">Environmental Pollutants</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057105" MajorTopicYN="N">Nuclear Receptor Subfamily 4, Group A, Member 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011987" MajorTopicYN="N">Receptors, Steroid</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19548348</ArticleId>
        <ArticleId IdType="doi">10.1021/tx8001934</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15488464</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0003-9861</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>431</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Archives of biochemistry and biophysics</Title>
          <ISOAbbreviation>Arch Biochem Biophys</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ebselen augments its peroxidase activity by inducing nrf-2-dependent transcription.</ArticleTitle>
        <Pagination>
          <StartPage>161</StartPage>
          <EndPage>168</EndPage>
          <MedlinePgn>161-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Ebselen is an organoselenium compound that acts as a glutathione peroxidase mimic. Since ebselen is a hydrophobic, thio-reactive compound capable of interacting with Keap-1, we tested its ability to activate nrf-2-dependent responses in the human hepatocarcinoma derived cell line, HepG2. Ebselen (25 microM) increased expression of an nrf-2 response element reporter in transient transfection experiments by 4-fold. Although, the induction was lower than that observed with classic nrf-2 inducer, sulforaphane (10 microL; 7-fold), ebselen also induced expression of native NAD(P)H:quinone oxidoreductase (1.6-fold) activity; induction of this protein is known to be dependent on nrf-2 action. Treatment of HepG2 cells with ebselen increased glutathione levels after 12 (1.5-fold) or 24 (1.9-fold)h of treatment. Treatment of the cells with either sulforaphane or ebselen 24 h prior to treatment with varying concentrations of t-butyl hydroperoxide increased the half maximal lethal dose from 28 to 42 microM and 58 microM for sulforaphane and ebselen, respectively. The protective effects of ebselen treatment were greater with pretreatment (IC50=58 microM) than simultaneous addition (IC50=45 microM). The protein synthesis inhibitor cycloheximide blocked increases in intracellular glutathione synthesis and partially blocked the protective effects of this regimen on increasing cell survival following t-butyl hydroperoxide treatment. Likewise co-treatment with the MEK 1 inhibitor, PD98059, which has been shown to inhibit nrf-2-dependent gene activation, partially inhibited the ebselen-dependent increases in IC50 while not affecting the control cells. We conclude that nrf-2 activation augments the role of ebselen as an antioxidant or by indirect induction of cellular antioxidant defences.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tamasi</LastName>
            <ForeName>Viola</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, KY 40292, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeffries</LastName>
            <ForeName>Julianne M</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arteel</LastName>
            <ForeName>Gavin E</ForeName>
            <Initials>GE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Falkner</LastName>
            <ForeName>K Cameron</ForeName>
            <Initials>KC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R03-AG202970-01</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arch Biochem Biophys</MedlineTA>
        <NlmUniqueID>0372430</NlmUniqueID>
        <ISSNLinking>0003-9861</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001393">Azoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051268">GA-Binding Protein Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054833">Isoindoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016566">Organoselenium Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>40X2P7DPGH</RegistryNumber>
          <NameOfSubstance UI="C042986">ebselen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.13.12.-</RegistryNumber>
          <NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.8.1.9</RegistryNumber>
          <NameOfSubstance UI="D013880">Thioredoxin-Disulfide Reductase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001393" MajorTopicYN="N">Azoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051268" MajorTopicYN="N">GA-Binding Protein Transcription Factor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018197" MajorTopicYN="N">Hepatoblastoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054833" MajorTopicYN="N">Isoindoles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016566" MajorTopicYN="N">Organoselenium Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020218" MajorTopicYN="N">Response Elements</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013880" MajorTopicYN="N">Thioredoxin-Disulfide Reductase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2004</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2004</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>10</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>10</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15488464</ArticleId>
        <ArticleId IdType="doi">10.1016/j.abb.2004.07.030</ArticleId>
        <ArticleId IdType="pii">S0003-9861(04)00433-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
